BioCryst Pharmaceuticals, Inc. is an American pharmaceutical company headquartered in Durham, North Carolina. The company is a late stage biotech company that focuses on oral drugs for rare and serious diseases. BioCryst's antiviral drug peramivir was approved by FDA in December 2014. Derived from Wikipedia licensed CC-BY-SA.
Open Access statistics for BioCryst Pharmaceuticals (United States), United States, covering academic research published from 2000 to 2024. Read More.
Open Access Percentage
35%
Total
Publications
224
Total Open
Publications
78
Total
Citations
5.6K
Open Access
Percentage
35%
Total
Publications
224
Total Open
Publications
78
Total
Citations
5.6K
Breakdown
Publisher Open
15%
Both
15%
Other Platform Open
6%
Closed
64%
Percentage of Open Access over time
Publisher Open
Both
Other Platform Open
Closed
Volume of Open Access over time
Open
Closed
Publisher Open
OA Journal 44%
30
Hybrid 16%
11
No Guarantees 40%
27
Other Platform Open
Domain 66%
31
Other Internet 28%
13
Institution 23%
11
Public 2%
1
Preprint 0%
0
Other Platform Locations
Name | Platform Type | Publications |
---|---|---|
PubMed Central | Domain | 31 |
DOI | Other Internet | 13 |
Washington University School of Medicine - Digital Commons@Becker | Institution | 3 |
Goethe University Frankfurt - Publication Server of Goethe University Frankfurt am Main | Institution | 3 |
University of Zurich - Zurich Open Repository and Archive | Institution | 2 |
University of Southern Denmark - University of Southern Denmark Research Portal | Institution | 2 |
Europe PMC | Domain | 2 |
Virginia Tech - VTechWorks | Institution | 1 |
Université de Lille (University Of Lille - LillOA) | Institution | 1 |
Universita Degli Studi Di Milano - Archivio Istituzionale della Ricerca | Institution | 1 |